{"context_annotations": [{"domain": {"id": "123", "name": "Ongoing News Story", "description": "Ongoing News Stories like 'Brexit'"}, "entity": {"id": "1220701888179359745", "name": "COVID-19"}}, {"domain": {"id": "46", "name": "Brand Category", "description": "Categories within Brand Verticals that narrow down the scope of Brands"}, "entity": {"id": "781974596157181956", "name": "Online Site"}}, {"domain": {"id": "47", "name": "Brand", "description": "Brands and Companies"}, "entity": {"id": "10047963346", "name": "Reuters", "description": "Reuters"}}], "public_metrics": {"retweet_count": 171, "reply_count": 177, "like_count": 370, "quote_count": 280}, "entities": {"urls": [{"start": 85, "end": 108, "url": "https://t.co/TteSfb5Q19", "expanded_url": "https://reut.rs/3ch1xfe", "display_url": "reut.rs/3ch1xfe"}, {"start": 109, "end": 132, "url": "https://t.co/TteSfb5Q19", "expanded_url": "https://reut.rs/3ch1xfe", "display_url": "reut.rs/3ch1xfe"}]}, "lang": "en", "conversation_id": "1258180789214347265", "created_at": "2020-05-06T23:44:10.000Z", "text": "Will Gilead price its coronavirus drug remdesivir for public good or company profit? https://t.co/TteSfb5Q19 https://t.co/TteSfb5Q19", "reply_settings": "everyone", "author_id": "1652541", "source": "SocialFlow", "possibly_sensitive": false, "id": "1258180789214347265"}